#IDMastodon @lancetrespirmed #Drugdevelopment Efficacy of #ravulizumab - Inhibiting C5 in patients with severe #COVID19โ The incorrect target?
๐ https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(23)00189-3/fulltext
๐ https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00297-1/fulltext
๐ https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(23)00082-6/fulltext#relatedClinic
๐ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070741/
#IDMastodon #DrugDevelopment #ravulizumab #COVID19
#IDMastodon #Drugdiscovery #Drugdevelopment @DDWJournal #Antibody discovery: Breakthroughs accelerating therapeutic antibodiesย .Trend and Challenge for therapeutic antibody in pandemic era
https://7915828.fs1.hubspotusercontent-na1.net/hubfs/7915828/DDW%20eBOOK%20ANTIBODY%20DISCOVERY_PROTECTED_FINAL.pdf?hsCtaTracking=b9795c08-6d89-4543-97ad-90cc3c6eae68%7C7aadb240-d29f-4505-a29e-578edfcc66da
#IDMastodon #DrugDiscovery #DrugDevelopment #antibody
@cyrilpedia nice piece, and also informative. Had missed the black box warning on the whole JAK Stat family! Is the increased cardiovascular risk dose / time dependent, or is it idiosyncratic?
#Immunology #drugdiscovery
#drugdevelopment #alopecia
#immunology #DrugDiscovery #DrugDevelopment #alopecia
#IDMastodon #Viralimmunology #Drugdevelopment @asmicrobiology #Phase II #Clinicaltrial for evaluating the #antiviral activity, safety, efficacy, & #pharmacokinetics of #bemnifosbuvir in ambulatory patients with mild/moderate #COVID19 . Although the study ended early and did not meet the primary efficacy end point, bemnifosbuvir was well tolerated and did not contribute to all-cause mortality. vs placebo
#IDMastodon #viralimmunology #DrugDevelopment #phase #clinicaltrial #Antiviral #pharmacokinetics #bemnifosbuvir #COVID19
#IDMastodon #viraimmunotherapy #Clinicalreviews on the current & future #Drugdevelopment for #COVID19 therapies as the emergence of new variants of #SARSCoV2, it is expedient that various therapeutics are researched & developed for the containment of #COVID19 .
#IDMastodon #viraimmunotherapy #Clinicalreviews #DrugDevelopment #COVID19 #SarsCoV2
#IDMastodon #Drugdevelopment #Immunology @Nature
Not all viruses have high antigenic variability, but for #SARSCoV2, #influenza ,#HIV, it will remain a challenge, and those types of antibodies are pretty high risk in the near term, given the rate of viral evolution.
#IDMastodon #DrugDevelopment #immunology #SarsCoV2 #influenza #hiv
#IDMastodon #Immunopharmacology #Drugdevelopment #Microbiology #Clinicalreview Understanding the role & mechanistic actions of protein kinase inhibitors as an drug target for cancer and #COVID19
๐ https://link.springer.com/article/10.1007/s00203-023-03559-z
๐ https://link.springer.com/journal/203/volumes-and-issues/205-7
#IDMastodon #immunopharmacology #DrugDevelopment #microbiology #clinicalreview #COVID19
#publichealth #DrugDevelopment @fda_drug_info Approves First Oral #Antiviral (#Paxlovid / #nirmatrelvir tablets, co-packaged for oral use) for the treatment of mild-to-moderate #COVID19 in adults who are at high risk for progression to severe #COVID19, including hospitalization or death.
https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-antiviral-treatment-covid-19-adults?utm_medium=email&utm_source=govdelivery
#publichealth #DrugDevelopment #Antiviral #Paxlovid #nirmatrelvir #COVID19
#DrugDevelopment @NatRevDrugDisc #Clinicalreview Summarize progress with #COVID19 #DrugDiscovery based on accumulated findings since #COVID19pandemic began & a comprehensive list of clinical and preclinical inhibitors with #Antiviral activities.
๐https://www.nature.com/articles/s41573-023-00672-y
๐ https://www.nature.com/nrd/articles?type=review-article
๐งตby @imedverse
https://twitter.com/imedverse/status/1651032814467313664?s=61&t=Yz-0chnQVfpDSt8bfrGiCw
#DrugDevelopment #clinicalreview #COVID19 #DrugDiscovery #COVID19pandemic #Antiviral
#DrugDevelopment & #DrugDelivery #IDMastodon #Viralimmunology DRAVP: A Comprehensive Database of Antiviral Peptides and Proteins
๐ https://www.mdpi.com/1999-4915/15/4/820
๐ http://dravp.cpu-bioinfor.org
#DrugDevelopment #drugdelivery #IDMastodon #viralimmunology
#Cancerimmunotherapies #DrugDevelopment @cellpress
Understanding Role of #Bcells in the #tumormicroenvironment Multi-faceted organizers, regulators, and effectors of anti-#TumorImmunity
๐ https://www.cell.com/cancer-cell/fulltext/S1535-6108(23)00045-4?rss=yes&utm_source=dlvr.it&utm_medium=twitter
๐ https://www.cell.com/cancer-cell/issue?pii=S1535-6108(22)X0006-8
#cancerimmunotherapies #DrugDevelopment #Bcells #tumormicroenvironment #tumorimmunity
Happy #MedicineMonday! The #FDA just approved the first treatment for #RettSyndrome, a rare, genetic, neurological disorder affecting brain development. This condition affects about 1:10,000 females, males to a far rarer extent and leads to a loss of language and motor skills developed earlier in life.
The medication Daybue (trofinetide) is for people 2 or older, delivered orally or via gastrostomy tube.
#MedicineMonday #FDA #rettsyndrome #DrugDevelopment #RareDisease
#IDMastodon #Drugdevelopment @SciImmunology: In Vivo study identifies a #pyruvate-based pathway connecting #COVID19 and metabolic dysfunctionโsuggests certain insulin sensitizer drugs taken alongside #SARSCoV2 #antivirals could prevent lung damage.
๐ https://www.science.org/doi/10.1126/sciimmunol.adf0348
๐ https://www.science.org/
#IDMastodon #DrugDevelopment #pyruvate #COVID19 #SarsCoV2 #antivirals
#IDMastodon #COVID19 #DrugDevelopment @Nature @Molecules_MDPI #DNA #oligonucleotides as #Antivirals and #Vaccine Constituents against #SARSCov2 infection.A Prospective Tool for #immunesystem Tuning
๐ https://www.mdpi.com/1422-0067/24/2/1553
๐ https://www.mdpi.com/1420-3049/28/3/1038
๐ https://www.nature.com/articles/s41573-020-0075-7
๐ https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/oligonucleotide
๐ https://www.nature.com/nrd/
#IDMastodon #COVID19 #DrugDevelopment #dna #oligonucleotides #antivirals #Vaccine #SarsCoV2 #immunesystem
#Drugdevelopment #IDMastodon An insight overview on #COVID19 #mRNA #vaccines Advantageous, pharmacology, mechanism of action, and prospective considerations & The #COVID19Vaccines development landscape
๐ https://www.sciencedirect.com/science/article/pii/S1567576923002540
๐ https://www.sciencedirect.com/journal/international-immunopharmacology/vol/117/suppl/C
#DrugDevelopment #IDMastodon #COVID19 #mrna #vaccines #COVID19vaccines
#Drugdiscovery #Drugdevelopment Taking the Guesswork Out of Drug-Target Residence Times @TheScientistLLC
https://offers.the-scientist.com/hubfs/TS_PPL_BellBrook%20Labs_Biochemical%20Assay_Guide_404902/A_Guide_to_Measuring_Drug-Target_Residence_Times_With_Biochemical_Assays.pdf?_ga=2.120619528.1441729371.1677645196-1538659024.1677645196
#DrugDiscovery #DrugDevelopment
#IDMastodon #Drugdevelopment #Clinicaltrial #Clinicalresearch @ScienceTM Whatโs next for #COVID19 Vaccine Development ?
๐https://www.science.org/doi/10.1126/scitranslmed.abo2847
๐ https://www.science.org/toc/stm/15/683
#IDMastodon #DrugDevelopment #clinicaltrial #clinicalresearch #COVID19
#IDMastodon @aaas #Drugdevelopment This study was designed with the goal to identify broadly cross-reactive and cross-neutralizing monoclonal antibodies that could recognize all #SARSCoV2 variants of concern and likely remain effective against future VOC.
https://www.science.org/doi/epdf/10.1126/sciimmunol.ade0958
#IDMastodon #DrugDevelopment #SarsCoV2
RT @tmprowell
Hope @POTUS will talk about #LongCovid in State of the Union address. The US has millions of people newly disabled by a condition without effective treatment, with major health & economic implications. In summary, it belongs in #sotu2023. #MedTwitter #DrugDevelopment #regulatory
#LongCovid #sotu2023 #medtwitter #DrugDevelopment #Regulatory
#IDMastodon #Drugdevelopment #Mucosalimmunity @biorxivpreprint
Mucoactive drugs block #SARSCoV2 InfectionโจIn this #Clinicalreviews indicates that Intact MCT reduces SARS-CoV-2 infection, andโจits pharmacologic activation may be effective as an anti- #COVID19 treatment.
https://www.biorxiv.org/content/10.1101/2023.01.30.526308v1.full.pdf
#IDMastodon #DrugDevelopment #mucosalimmunity #SarsCoV2 #Clinicalreviews #COVID19